NCT02506933View on ClinicalTrials.gov

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 5, 2015

Primary Completion Date

January 25, 2018

Study Completion Date

June 9, 2026

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionChronic Lymphocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCytomegaloviral InfectionHodgkin LymphomaLymphadenopathyLymphoblastic LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative NeoplasmNon-Hodgkin Lymphoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Given IM

OTHER

Placebo

Given IM

Trial Locations (3)

77030

M D Anderson Cancer Center, Houston

91010

City of Hope Medical Center, Duarte

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Diavax Biosciences
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Diavax Biosciences

INDUSTRY

lead

City of Hope Medical Center

OTHER